Market closed
Sutro Biopharma/$STRO
Sutro Biopharma shares are trading lower after the company reported a Q1 loss wider than expected.
13 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sutro Biopharma
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Ticker
$STRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
310
ISIN
US8693671021
Website
Sutro Biopharma Metrics
BasicAdvanced
$81M
-
-$2.96
1.22
-
Price and volume
Market cap
$81M
Beta
1.22
52-week high
$5.17
52-week low
$0.52
Average daily volume
2.1M
Financial strength
Current ratio
2.603
Quick ratio
2.468
Long term debt to equity
35.143
Total debt to equity
51.914
Interest coverage (TTM)
-7.37%
Management effectiveness
Return on assets (TTM)
-34.74%
Return on equity (TTM)
-234.19%
Valuation
Price to revenue (TTM)
1.187
Price to book
1.77
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-0.378
Growth
Revenue change (TTM)
-59.64%
Earnings per share change (TTM)
66.79%
3-year revenue growth (CAGR)
0.09%
3-year earnings per share growth (CAGR)
8.96%
What the Analysts think about Sutro Biopharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sutro Biopharma stock.
Sutro Biopharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sutro Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sutro Biopharma News
AllArticlesVideos
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewsWire·2 days ago
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sutro Biopharma stock?
Sutro Biopharma (STRO) has a market cap of $81M as of May 10, 2025.
What is the P/E ratio for Sutro Biopharma stock?
The price to earnings (P/E) ratio for Sutro Biopharma (STRO) stock is 0 as of May 10, 2025.
Does Sutro Biopharma stock pay dividends?
No, Sutro Biopharma (STRO) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Sutro Biopharma dividend payment date?
Sutro Biopharma (STRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Sutro Biopharma?
Sutro Biopharma (STRO) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.